Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
Science Careers Booklet

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Science 2 December 2005:
Vol. 310. no. 5753, pp. 1442 - 1443
DOI: 10.1126/science.1122009

Perspectives

IMMUNOLOGY:
Tipping the Scales Toward More Effective Antibodies

Jenny M. Woof

Immunoglobulin G molecules, key mediators of immune protection and burgeoning therapeutic reagents, exist in different forms or subclasses. In her Perspective, Woof discusses new work by Nimmerjahn and Ravetch that reveals how, in some settings, the in vivo functional capabilities of each subclass may be predicted on the basis of differential interaction with specific cellular Fc receptors.


The author is in the Division of Pathology and Neuroscience, University of Dundee Medical School, Ninewells Hospital, Dundee DD1 9SY, UK. E-mail: j.m.woof{at}dundee.ac.uk

Read the Full Text



THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Complement-Dependent Tumor Cell Lysis Triggered by Combinations of Epidermal Growth Factor Receptor Antibodies.
M. Dechant, W. Weisner, S. Berger, M. Peipp, T. Beyer, T. Schneider-Merck, J. J. Lammerts van Bueren, W. K. Bleeker, P. W.H.I. Parren, J. G.J. van de Winkel, et al. (2008)
Cancer Res. 68, 4998-5003
   Abstract »    Full Text »    PDF »
Effector Mechanisms of Recombinant IgA Antibodies against Epidermal Growth Factor Receptor.
M. Dechant, T. Beyer, T. Schneider-Merck, W. Weisner, M. Peipp, J. G. J. van de Winkel, and T. Valerius (2007)
J. Immunol. 179, 2936-2943
   Abstract »    Full Text »    PDF »



ADVERTISEMENT
Click Me!

ADVERTISEMENT
Click Me!

To Advertise     Find Products


Science. ISSN 0036-8075 (print), 1095-9203 (online)